Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
ELI LILLY & Co director J. Erik Fyrwald reported an equity award tied to his board compensation. On the reported date, he acquired 9.572 shares of common stock at a reference price of $1,036.05 per share, bringing his directly held total to 75,120.322 shares. According to the disclosure, he elected to defer this award into stock units under the Lilly Directors' Deferral Plan, to be settled in shares of common stock after he separates from board service.
ELI LILLY & Co director Ralph Alvarez reported an equity award tied to his board compensation. He acquired 11.985 shares of common stock on February 17, 2026 at a reference price of $1,036.05 per share as a grant, bringing his directly held stake to 55,491.627 shares.
According to the disclosure, he elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan, which will be settled in common shares after he leaves board service. The filing also reports 758 shares held indirectly by a trust, with Alvarez disclaiming beneficial ownership beyond his economic interest.
ELI LILLY & Co SVP Donald A. Zakrowski exercised restricted stock units and had shares withheld for taxes. On the transaction date, 184 restricted stock units were converted into 184 common shares at $0.00 per share. To satisfy tax obligations, 81.553 common shares were disposed of at $1040.00 per share, leaving 3,525.89 directly owned shares and 1,728.57 common shares held indirectly through a 401(k) plan. Each restricted stock unit represents a contingent right to receive one share of common stock.
Eli Lilly & Co EVP & CFO Montarce Lucas reported equity award activity involving company stock. Lucas exercised or converted 368 restricted stock units, receiving the same number of Eli Lilly common shares. To cover tax obligations, 159.733 common shares were disposed of in a tax-withholding transaction at $1040 per share, leaving 16,258.473 common shares owned directly after these transactions.
Eli Lilly & Co executive Kenneth L. Custer reported routine equity transactions. On February 16, he exercised 207 restricted stock units, receiving 207 shares of common stock at no cost. On the same date, 91.311 shares were disposed of at $1,040 per share to satisfy tax withholding obligations, leaving him with 10,140.544 directly owned shares.
Adrienne S. Brown, EVP and President of Lilly Immunology at Eli Lilly & Co, exercised restricted stock units into common shares and had shares withheld to cover taxes. On the transaction date, 391 restricted stock units were converted into 391 shares of common stock at a stated price of $0.0000 per share.
Following this derivative exercise/conversion, a tax-withholding disposition of 169.966 common shares was reported at $1040.0000 per share to satisfy tax obligations. After these transactions, Brown directly owned 5,142.342 shares of Eli Lilly common stock.
Eli Lilly executive insider filing shows a corrected share adjustment. On February 9, 2026, the reporting officer (EVP & CIDO) is shown as having acquired 4,599.164 shares of Eli Lilly common stock at $1,044.67 per share. After this adjustment, the executive directly owns 26,396.534 shares. The accompanying note explains this amended Form 4 corrects an earlier over-withholding of shares for tax obligations caused by an administrative error.
Eli Lilly and Company filed its annual report for the year ended December 31, 2025, outlining a global human pharmaceuticals business focused on cardiometabolic health, oncology, immunology, and neuroscience. Key growth drivers include diabetes, obesity, cardiovascular, cancer, immunology, and migraine/Alzheimer’s medicines such as Mounjaro/Zepbound, Trulicity, Jardiance, Verzenio, Omvoh, Taltz, Emgality, and Kisunla.
The company highlights extensive patent and data exclusivity across major products, with key expiries stretching into the 2030s and 2040s, and notes heavy reliance on intellectual property protection. It details a complex regulatory environment across the U.S., EU, Japan, China, and other markets, including the impact of biosimilars, generics, compounding and counterfeit incretin products, and evolving FDA, EMA, and other oversight.
Lilly discusses significant pricing and reimbursement pressures, including the U.S. Inflation Reduction Act, 340B dynamics, and an announced preliminary voluntary agreement with the U.S. government to lower certain prices and expand access, especially for obesity medicines. The report also describes large manufacturing capacity expansions globally, a 50,000-person workforce with 12,000 in R&D, and an experienced executive team. Shares of common stock outstanding were 943,357,420 as of February 9, 2026.
Eli Lilly & Co senior vice president, finance, and chief accounting officer Donald A. Zakrowski acquired additional company equity on February 9, 2026. He received 583.784 shares of common stock as a grant or award at $1,044.67 per share, bringing his directly held common stock to 3,423.443 shares.
He also received a grant of 199.472 restricted stock units, each representing a contingent right to one share of common stock, with both exercisable and expiration dates of February 16, 2029. In addition, 1,728.57 common shares are held indirectly through a 401(k) plan.
Eli Lilly executive Ilya Yuffa reported an acquisition of company stock through an equity award. On 02/09/2026, he received 4,162.504 shares of Eli Lilly common stock in a grant or other acquisition at a price of $1,044.67 per share. Following this award, he directly holds 32,304.111 shares of Eli Lilly common stock as EVP & President, LLY USA & Global Capabilities.